Article Text

Download PDFPDF
CASE REPORT
Good response of an aggressive rare variant of signet ring cell carcinoma of prostate with hormonal therapy
  1. Deviprasad Tiwari,
  2. Brusabhanu Nayak,
  3. Amlesh Seth
  1. All India Institute of Medical Sciences, New Delhi, India
  1. Correspondence to Dr Brusabhanu Nayak, Assistant Professor, Urology; brusabhanu{at}gmail.com

Summary

Primary signet ring cell carcinoma (SRCC) of the prostate is a rare entity, characterised by its aggressive nature and dismal prognosis. We report a case of an advanced SRCC of the prostate presenting as a large pelvic mass with obstructive uropathy and rectal involvement managed by complete androgen blockade. At 24 months follow-up, the patient has no evidence of progression or metastasis. Aggressive management with multimodality approach combining surgery, radiation and hormonal ablation can result in long disease-free survival in some patients, despite the aggressive nature of this disease.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors DT is responsible for data acquisition, manuscript writing and literature review. BN is responsible for manuscript editing and literature review. AS is responsible for manuscript editing.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.